Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pharmathene Inc (PIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 48,174
  • Shares Outstanding, K 68,820
  • Annual Sales, $ 5,230 K
  • Annual Income, $ 193,850 K
  • 36-Month Beta 2.45
  • Price/Sales 9.77
  • Price/Cash Flow 0.24
  • Price/Book 2.42
  • Price/Earnings ttm 0.25
  • Earnings Per Share ttm 2.95
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 2.91 on 02/06/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.68 +2.94%
on 04/25/17
0.93 -24.73%
on 03/28/17
-0.08 (-10.26%)
since 03/24/17
3-Month
0.47 +48.94%
on 02/06/17
3.30 -78.79%
on 02/03/17
-2.55 (-78.46%)
since 01/25/17
52-Week
0.47 +48.94%
on 02/06/17
3.50 -80.00%
on 01/19/17
-1.79 (-71.89%)
since 04/25/16

Most Recent Stories

More News
PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, announced today that it has established a record date and meeting date for a special meeting...

PIP : 0.70 (-5.41%)
Altimmune to Present at the BIO CEO & Investor Conference

Altimmune, Inc., a clinical stage immunotherapeutics company targeting infectious diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO & Investor Conference on...

PIP : 0.70 (-5.41%)
Research Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma

Stock-Callers.com brings focus back on the Biotechnology industry to see how some equities have fared over the last few trading sessions. Under evaluation this morning are: PharmAthene Inc. (NYSE MKT:...

CORT : 9.27 (+0.76%)
ITEK : 1.98 (+1.54%)
PIP : 0.70 (-5.41%)
NAVB : 0.51 (+10.87%)
Blog Coverage PharmAthene and Altimmune Announced a Merger; Set to Establish Immunotherapeutic Collaboration

Upcoming AWS Coverage on Celgene

CELG : 125.52 (+1.92%)
PIP : 0.70 (-5.41%)
PharmAthene Declares $2.91 Special Cash Dividend on Common Stock

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that its Board of Directors has declared a special one-time cash dividend of...

PIP : 0.70 (-5.41%)
SIGA : 3.5300 (+1.15%)
PharmAthene Receives Final Payment from SIGA of $83.9 Million

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today received a final payment from SIGA Technologies, Inc. of $83.9 million which fully satisfies...

PIP : 0.70 (-5.41%)
SIGA : 3.5300 (+1.15%)
PharmAthene Reports Third Quarter 2016 Financial and Operational Results

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the third quarter of 2016.

PIP : 0.70 (-5.41%)
SIGA : 3.5300 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror....

See More

Support & Resistance

2nd Resistance Point 0.78
1st Resistance Point 0.74
Last Price 0.70
1st Support Level 0.67
2nd Support Level 0.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.